CommercialPrior AuthMedium impact
08.01.88b, Allogeneic Processed Thymus Tissue-agdc (Rethymic®)
Independence Blue Cross·Pharmacy, Allergy & Immunology, Pediatrics·Pharmacy
Effective date
Nov 17, 2025
We identified it
Jun 19, 2026
Summary
This policy update modifies the medical necessity criteria for Rethymic® (allogeneic processed thymus tissue-agdc), a specialty pharmaceutical product. The billing team must ensure claims for this medication are submitted with updated medical necessity documentation requirements to avoid denials. Specific criteria details are not provided in the source material, so the full policy text must be reviewed and implemented.
Action Required
By November 17, 2025: Billing team must obtain and review the complete policy text at the provided URL to identify specific medical necessity criteria for Rethymic® (HCPCS J7511). Update billing software, prior authorization workflows, and provider documentation templates to enforce these criteria. Communicate requirements to providers and ensure all Rethymic® claims include required medical necessity documentation. Claims submitted without proper documentation will be denied.